Edition:
United Kingdom

Diffusion Pharmaceuticals Inc (DFFN.OQ)

DFFN.OQ on NASDAQ Stock Exchange Capital Market

0.52USD
19 Jun 2018
Change (% chg)

$-0.03 (-4.55%)
Prev Close
$0.55
Open
$0.54
Day's High
$0.55
Day's Low
$0.52
Volume
12,581
Avg. Vol
51,331
52-wk High
$3.02
52-wk Low
$0.44

Latest Key Developments (Source: Significant Developments)

Diffusion Pharmaceuticals Announces $12 Mln Underwritten Public Offering
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Diffusion Pharmaceuticals Inc ::DIFFUSION PHARMACEUTICALS ANNOUNCES $12 MILLION UNDERWRITTEN PUBLIC OFFERING.DIFFUSION PHARMACEUTICALS- ‍PRICED PUBLIC OFFERING OF 15 MILLION SHARES, WITH WARRANTS TO PURCHASE UP TO 15 MILLION SHARES, AT $0.80/SHARE, ASSOCIATED WARRANT​.  Full Article

Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial With TSC In Glioblastoma Multiforme
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Diffusion Pharmaceuticals Inc ::DIFFUSION PHARMACEUTICALS BEGINS PHASE 3 CLINICAL TRIAL WITH TSC IN GLIOBLASTOMA MULTIFORME.DIFFUSION PHARMA - PROJECTS ENROLLMENT WILL BE COMPLETED BY EARLY 2019, WITH INTERIM SAFETY, EFFICACY DATA POSSIBLE IN 2020, TRIAL COMPLETION IN 2021.  Full Article

Diffusion Pharma Files For Stock Offering For Up To About $15 Mln
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Diffusion Pharmaceuticals Inc ::DIFFUSION PHARMACEUTICALS FILES FOR STOCK OFFERING FOR UP TO ABOUT $15 MILLION - SEC FILING.  Full Article

Diffusion Pharmaceuticals reports qtrly net income per diluted share $0.20‍​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Diffusion Pharmaceuticals Inc :Diffusion Pharmaceuticals Inc qtrly net income per diluted share $0.20‍​.Diffusion Pharmaceuticals Inc - ‍remain on track to begin enrolling patients by end of 2017 for tsc glioblastoma phase 3 pivotal study​.Diffusion Pharmaceuticals Inc - ‍awaiting confirmation from Nasdaq that co demonstrated compliance with all applicable requirements for continued listing​.  Full Article

Diffusion Pharma gets FDA protocol guidance for phase 3 trial with TSC
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Diffusion Pharmaceuticals Inc :Diffusion Pharmaceuticals receives final FDA protocol guidance for phase 3 clinical trial with TSC in patients newly diagnosed with inoperable glioblastoma multiforme.Has responded to all outstanding points raised by FDA, plans to begin trial under protocol agreed to by FDA by end of 2017​.Trial to compare survival at 2 yrs of patients receiving TSC concurrent with chemo, radiation with patients receiving SOC alone​.  Full Article